217326-69-7

Basic information

• Product Name: 4-BroMo-2-Methyl-1,3-benzoxazole
• Synonyms: 4-BroMo-2-Methyl-1,3-benzoxazole;4-bromo-2-methylbenzo[d]oxazole;4-bromo-2-methylBenzoxazole;PCDOABUEJUJMKB-UHFFFAOYSA-N
• CAS NO: 217326-69-7
• Molecular Formula: C8H6BrNO
• Molecular Weight: 212.04334
• Mol File: 217326-69-7.mol

Chemical Properties

• Boiling Point: 264.8±13.0 °C(Predicted)
• Appearance: /
• Density: 1.606±0.06 g/cm3(Predicted)
• PKA: -1.31±0.30(Predicted)
• CAS DataBase Reference: 4-BroMo-2-Methyl-1,3-benzoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2-Methyl-1,3-benzoxazole(217326-69-7)
• EPA Substance Registry System: 4-BroMo-2-Methyl-1,3-benzoxazole(217326-69-7)

Safety Data

• Hazardous Substances Data: 217326-69-7(Hazardous Substances Data)

Upstream product

• 614-76-6 N-acetyl-2-bromoaniline 
• 615-36-1 2-bromoaniline 
• 116435-77-9 2-amino-3-bromophenol 
• 78-39-7 Triethyl orthoacetate 

Relevant articles and documents

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Synthesis of 2-methylbenzoxazoles directly from: N -phenylacetamides catalyzed by palladium acetate

A method to synthesize 2-methylbenzoxazoles directly from N-phenylacetamides catalyzed by Pd(OAc)2 in the presence of K2S2O8 and TfOH has been developed. The desired products were obtained in moderate to excellent yields. This approach provides a facile procedure to prepare benzoxazoles with available substrates. It is found that TfOH is the key factor for this cyclization reaction. A plausible mechanism of the reaction is proposed according to the control reactions and the literature.

Biarylalkanoic acids as cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.